TY  - EJOU
AU  - LI, XIAOYIN 
AU  - WANG, QIAN 
AU  - LIANG, HONGFENG 
AU  - CHEN, SHISHENG 
AU  - CHEN, HAIWEN 
AU  - LU, YAOYONG 
AU  - YANG, CHANGFU 

TI  - IGF2BP3-induced activation of EIF5B contributes to progression of hepatocellular carcinoma cells
T2  - Oncology Research

PY  - 2022
VL  - 30
IS  - 2
SN  - 1555-3906

AB  - In this study, we investigated the functional role of eukaryotic initiation factor 5B (EIF5B) in hepatocellular carcinoma (HCC) and the underlying mechanisms. Bioinformatics analysis demonstrated that the EIF5B transcript and protein levels as well as the EIF5Bcopy number were significantly higher in the HCC tissues compared with the non-cancerous liver tissues. Down-regulation of EIF5B significantly decreased proliferation and invasiveness of the HCC cells. Furthermore, EIF5B knockdown suppressed epithelial-mesenchymal transition (EMT) and the cancer stem cell (CSC) phenotype. Down-regulation of EIF5B also increased the sensitivity of HCC cells to 5-fluorouracil (5-FU). In the HCC cells, activation of the NF-kappa B signaling pathway and IkB phosphorylation was significantly reduced by EIF5B silencing. IGF2BP3 increased the stability of the EIF5B mRNA in an m6A-dependent manner. Our data suggested that EIF5B is a promising prognostic biomarker and therapeutic target in HCC.
KW  - EIF5B
KW  -  NF-κB
KW  -  Epithelial-mesenchymal transition
KW  -  Cancer stem cells
KW  -  N6-methyladenosine
KW  -  Hepatocellular carcinoma

DO  - 10.32604/or.2022.026511